Top advances of the year: Developments of immunotherapy in cutaneous squamous cell carcinoma, 2023-2024.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40445861.
- Also identified by DOI 10.1002/cncr.35920 and PMC identifier 12124471.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antibodies against PD-1 (PD1i), such as cemiplimab and pembrolizumab, have demonstrated significant efficacy in advanced, unresectable cutaneous squamous cell carcinoma (cSCC). These agents elicit durable responses in approximately 45% of patients, contributing to improved aesthetic, functional, and survival outcomes in a subset of individuals with advanced cSCC. This review highlights recent and ongoing research investigating the safety and efficacy of immune checkpoint inhibitors for cSCC in the curative intent perioperative settings, advanced/metastatic setting, and within the immunocompromised patient populations.
Medical subject headings
- Skin Neoplasms
- Carcinoma, Squamous Cell
- Immunotherapy
- Immune Checkpoint Inhibitors